China NMPA Drug Inspection - Yabao Pharmaceutical Group Co., Ltd - Mu Xiang Shun Qi Wan
China NMPA drug inspection for Yabao Pharmaceutical Group Co., Ltd published May 24, 2018. Drug: Mu Xiang Shun Qi Wan. The National Medical Products Administration (NMPA) of China issued an announcement on May 24, 2018, detailing non-compl
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Yabao Pharmaceutical Group Co., Ltd published May 24, 2018. Drug: Mu Xiang Shun Qi Wan. The National Medical Products Administration (NMPA) of China issued an announcement on May 24, 2018, detailing non-compl
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox